Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jan 27, 2010

Premium

Vance Vanier will take over the president and CEO positions at Navigenics. Vanier started at Navigenics in 2008 and was serving as chief medical officer of the consumer genomics firm.

Before joining Navigenics, Vanier was a partner at Mohr Davidow Ventures. He also is a clinical faculty member at Stanford University Medical Center.


Klaus Lindpaintner has been hired by Strategic Diagnostics as VP of research and development and chief scientific officer.

Lindpaintner, who was director of Roche Molecular Medicine Laboratories and was global head of its policy and external affairs, will begin in his new position in February.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.